3 Top Biotech Stocks to Buy in December [The Motley Fool]
Axsome Therapeutics, Inc. (AXSM)
Last axsome therapeutics, inc. earnings: 3/12 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
axsome.com
Company Research
Source: The Motley Fool
3 Top Biotech Stocks to Buy in December Will biotech stocks One's a dividend investor's dream. Another is a clinical-stage biotech that has plenty of big news on the way. And the third is arguably the best biotech stock on the market right now AbbVie ( NYSE:ABBV Axsome Therapeutics NASDAQ:AXSM Vertex Pharmaceuticals NASDAQ:VRTX Image source: Getty Images. . AbbVie If you're looking for a stock with an absolutely mouthwatering dividend, look no further than AbbVie. Its dividend currently yields close to .%. And AbbVie has boosted its dividend payout by a whopping 9% since becoming a standalone company in 0. No, AbbVie probably won't deliver earth-shattering growth anytime soon. Its top-selling drug, Humira, faces biosimilar It already has a couple of blood cancer drugs generating strong sales growth with Imbruvica and Venclexta. New immunology drugs Rinvoq and Skyrizi ranked No. and No. , respectively, on EvaluatePharma's list of the top new drug launches of 09 The other key part of A
Show less
Read more
Impact Snapshot
Event Time:
AXSM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AXSM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AXSM alerts
High impacting Axsome Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
AXSM
News
- Axsome Therapeutics (AXSM) had its price target raised by UBS Group AG from $251.00 to $259.00. They now have a "buy" rating on the stock.MarketBeat
- Is This Healthcare Stock a Millionaire Maker? [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- Is This Healthcare Stock a Millionaire Maker? [Yahoo! Finance]Yahoo! Finance
- Axsome Therapeutics to Report First Quarter 2026 Financial Results on May 4GlobeNewswire
- Axsome Therapeutics Acquires Selective PDE10A Inhibitor Balipodect for the Treatment of Schizophrenia and Other Neuropsychiatric ConditionsGlobeNewswire
AXSM
Earnings
- 2/23/26 - Beat
AXSM
Sec Filings
- 4/1/26 - Form 8-K
- 3/26/26 - Form SCHEDULE
- 2/27/26 - Form 4
- AXSM's page on the SEC website